
Deepak L. Bhatt, James Scheiman, Neena S. Abraham, Elliott M. Antman, Francis K.L. Chan, Curt D. Furberg, David A. Johnson, Kenneth W. Mahaffey and Eamonn M. Quigley

*Circulation* 2008;118;1894-1909; originally published online Oct 3, 2008;
DOI: 10.1161/CIRCULATIONAHA.108.191087
Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/cgi/content/full/118/18/1894
ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents

WRITING COMMITTEE MEMBERS
Deepak L. Bhatt, MD, FACC, FAHA, Co-Chair; James Scheiman, MD, FACC, Co-Chair*
Neena S. Abraham, MD, MSCE, FACG*; Elliott M. Antman, MD, FACC, FAHA†; Francis K.L. Chan, MD, FACC*; Curt D. Furberg, MD, FAHA‡; David A. Johnson, MD, FACC*; Kenneth W. Mahaffey, MD, FACC; Eamonn M. Quigley, MD, FACC*

ACCF TASK FORCE MEMBERS
Robert A. Harrington, MD, FACC, Chair; Eric R. Bates, MD, FACC; Charles R. Bridges, MD, MPH, FACC; Mark J. Eisenberg, MD, MPH, FACC; Victor A. Ferrari, MD, FACC; Mark A. Hlatky, MD, FACC; Sanjay Kaul, MBBS, FACC; Jonathan R. Lindner, MD, FACC‡; David J. Moliterno, MD, FACC; Debabrata Mukherjee, MD, FACC; Richard S. Schofield, MD, FACC‡; Robert S. Rosenson, MD, FACC; James H. Stein, MD, FACC; Howard H. Weitz, MD, FACC; Deborah J. Wesley, RN, BSN

TABLE OF CONTENTS
Preamble .................................................... 1895
Introduction ................................................ 1895
Prevalence of Use—NSAIDs/Aspirin (ASA) ............ 1895
Mechanisms of GI Injury—NSAIDs ..................... 1895
Mechanisms of Gastroduodenal Injury—Clopidogrel ....................................... 1896
1. GI Complications of ASA and Non-ASA NSAIDs . 1896
2. GI Effects of ASA ................................... 1897
3. GI Effects of Combined ASA and Anticoagulant Therapy .............................................. 1898
4. GI Effects of Clopidogrel ........................... 1898
5. GI Effects of Combined Clopidogrel and Anticoagulant Therapy .............................................. 1899
6. Treatment and Prevention of ASA- and NSAID-Related Gastroduodenal Injury ..................... 1899
7. Role of H pylori ..................................... 1901
   A. Diagnosis of H pylori .............................. 1901
   B. Tests for Active H pylori .......................... 1901
   C. Treatment of H pylori ............................. 1902
8. Discontinuation of Antiplatelet Therapy Because of Bleeding ............................................. 1902
9. Endoscopy in Patients on Mono- or Dual Antiplatelet Therapy .............................................. 1903
   Summary ................................................... 1903
   References ................................................. 1906
   Appendix 1................................................. 1908
   Appendix 2................................................. 1908

*American College of Gastroenterology representative.
†American Heart Association representative.
‡Former Task Force member during this writing effort.

This document was approved by the American College of Cardiology Foundation (ACCF) Board of Trustees in August 2008, by the American College of Gastroenterology (ACG) Board of Trustees in June 2008, and by the American Heart Association (AHA) Science Advisory and Coordinating Committee in August 2008.


© 2008 by the American College of Cardiology Foundation, American College of Gastroenterology, and the American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.108.191087

This article has been copublished in the Journal of the American College of Cardiology and the American Journal of Gastroenterology.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American College of Gastroenterology (www.acg.gi.org), and the American Heart Association (my.americanheart.org). A copy of the document is also available at http://www.americanheart.org/presenter.jhtml?identifier=3003999 by selecting either the “topic list” link or the “chronological list” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the “Permission Request Form” appears on the right side of the page.

(Circulation. 2008;118:1894-1909.)

This document was approved by the American College of Cardiology Foundation (ACCF) Board of Trustees in August 2008, by the American College of Gastroenterology (ACG) Board of Trustees in June 2008, and by the American Heart Association (AHA) Science Advisory and Coordinating Committee in August 2008.


© 2008 by the American College of Cardiology Foundation, American College of Gastroenterology, and the American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.108.191087

This article has been copublished in the Journal of the American College of Cardiology and the American Journal of Gastroenterology.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology (www.acc.org), the American College of Gastroenterology (www.acg.gi.org), and the American Heart Association (my.americanheart.org). A copy of the document is also available at http://www.americanheart.org/presenter.jhtml?identifier=3003999 by selecting either the “topic list” link or the “chronological list” link. To purchase additional reprints, call 843-216-2533 or e-mail kelle.ramsay@wolterskluwer.com.

Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?identifier=4431. A link to the “Permission Request Form” appears on the right side of the page.

(Circulation. 2008;118:1894-1909.)

© 2008 by the American College of Cardiology Foundation, American College of Gastroenterology, and the American Heart Association, Inc.

Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIRCULATIONAHA.108.191087

This article has been copublished in the Journal of the American College of Cardiology and the American Journal of Gastroenterology.
Preamble
This document has been developed by the American College of Cardiology Foundation (ACCF) Task Force on Clinical Expert Consensus Documents, the American College of Gastroenterology (ACG), and the American Heart Association (AHA). Expert consensus documents (ECDs) are intended to inform practitioners, payers, and other interested parties of the opinion of the ACCF and document cosponsors concerning evolving areas of clinical practice and/or technologies that are widely available or new to the practice community. Topics chosen for coverage by ECDs are so designed because the evidence base, the experience with technology, and/or the clinical practice are not considered sufficiently well developed to be evaluated by the formal American College of Cardiology/American Heart Association (ACCF/AHA) practice guidelines process. Often the topic is the subject of ongoing investigation. Thus, the reader should view ECDs as the best attempt of the ACCF and other cosponsors to inform and guide clinical practice in areas where rigorous evidence may not be available or the evidence to date is not widely accepted. When feasible, ECDs include indications or contraindications. Topics covered by ECDs may be addressed subsequently by the ACC/AHA Practice Guidelines Committee as new evidence evolves and is evaluated.

The Task Force on ECDs makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, all members of the writing panel are asked to provide disclosure statements of all such relationships that might be perceived as real or potential conflicts of interest to inform the writing effort. These statements are reviewed by the parent task force, reported orally to all members of the writing panel at the first meeting, and updated as changes occur. The relationships with industry information for writing committee members and peer reviewers are listed in Appendixes 1 and 2, respectively.

Robert A. Harrington, MD, FACC
Chair, ACCF Task Force on Clinical Expert Consensus Documents

Introduction
The use of antiplatelet therapies continues to increase as a result of accumulation of evidence of benefits in both primary and secondary treatment strategies for cardiovascular disease.1,2 These antiplatelet agents, however, have recognizable risks—in particular, gastrointestinal (GI) complications such as ulceration and related bleeding. These risks may be further compounded by the ancillary use of other adjunctive medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and anticoagulants. Given the high prevalence of antiplatelet therapy in clinical practice, coupled with an increased emphasis on their extended use, especially after implantation of a drug-eluting stent,3,4 it is imperative that physicians know the potential benefits and the associated risks of antiplatelet therapy for primary or secondary prevention of cardiac ischemic events when combined with NSAID agents. Only with this understanding can physicians appropriately and fully evaluate the risk profile for each patient and either change medications or initiate prophylactic therapy in an attempt to reduce GI complications. This document provides consensus recommendations from the ACCF, the AHA, and the ACG on the combined use of antiplatelets and NSAID agents.

Many NSAIDs, both selective and nonselective, increase the risk of cardiovascular and cerebrovascular events. This issue was addressed in a scientific statement from the AHA.5 In terms of cardiovascular, GI, renal, and hypertension-inducing risks, there are important differences among the NSAIDs (especially the cyclo-oxygenase-2 [COX-2] inhibitors), which should also be understood and considered in managing patients in need of these agents.6 The AHA statement introduces a stepped-care approach for selection of drugs to manage musculoskeletal discomfort in patients with known cardiovascular disease or risk factors for ischemic heart disease, based on the risk/benefit balance from a cardiovascular perspective. A further discussion of the cardiovascular and cerebrovascular risks of NSAIDs is beyond the scope of this report but may be found in several reviews.5,7

Prevalence of Use—NSAIDs/Aspirin (ASA)
The use of NSAIDs, including ASA, is common in the treatment of pain, inflammation, and fever. Additionally, low-dose ASA is used routinely in primary and secondary prophylaxis of cardiovascular and cerebrovascular events. These agents, both through prescription and over-the-counter (OTC) use, are the most widely used class of medications in the United States.8 Not surprisingly, NSAID use increases among the elderly. In a survey of people 65 years of age and older, 70% used NSAIDs at least once weekly, and 34% used them at least daily. The prevalence of at least weekly ASA usage was 60%.9 More than 111 million NSAID prescriptions were written in 2004.10

Recognizably, much of this usage comes from noncardiac indications, such as arthritis and related musculoskeletal complaints, in particular. In 1990, the estimated prevalence of self-reported arthritis in the United States was 37.9 million cases, or 15% of the population. By 2020, it is projected that 59.4 million will be affected—a 57% increase from 1990.11 As the incidence of arthritis complaints increases, the use of prescription and OTC NSAIDs is also expected to increase.

Mechanisms of GI Injury—NSAIDs
A complete discussion of the pathogenesis of ASA- and NSAID-associated injury is beyond the scope of this article; however, ASA, like all NSAIDs, injures the gut by causing topical injury to the mucosa and systemic effects induced by prostaglandin depletion. Tissue prostaglandins are produced via 2 pathways: a COX-1 and a COX-2 pathway. The COX-1 pathway is the predominant constitutive pathway; prostaglandins derived from this enzyme mediate many effects, most notably facilitating gastroduodenal cytoprotection, renal perfusion, and platelet activity. The COX-2 pathway, in contrast, is inducible by inflammatory stimuli and mediates effects through prostaglandins, which result in inflammation, pain, and fever.

Inhibition of the COX-1 pathway blocks production of prostaglandins that play an important protective role in the
stomach by increasing mucosal blood flow and stimulating the synthesis and secretion of mucus and bicarbonate, as well as promoting epithelial proliferation. Accordingly, the inhibition of these prostaglandins impairs these protective factors, resulting in a gastric environment that is more susceptible to topical attack by endogenous factors, such as acid, pepsin, and bile salts. A major consequence of prostaglandin depletion is to create an environment that is conducive to peptic ulcer formation and serious GI complications. Since prostaglandins are essential to both the maintenance of intact GI defenses and normal platelet function, nonselective NSAIDs such as ASA promote ulcer formation as well as bleeding.

Because COX-2 is the primary intended target for anti-inflammatory drug therapy, agents that selectively block COX-2, while having little to no effect on COX-1, should result in effective pain relief with reduced GI toxicity. This concept, called the “COX-2 hypothesis,” has been challenged by data from animal studies, which indicated that both COX-1 and COX-2 must be inhibited for gastric ulceration to occur. Interestingly, while the selective inhibition of either COX-1 or COX-2 alone failed to cause gastric damage, inhibition of both COX isoforms produced gastric ulceration. Thus, the explanation for reduced GI toxicity for COX-2–specific inhibitors may be their lack of dual COX inhibition rather than their COX-1–sparing effects.

In this framework, taking both a cardioprotective dose of ASA (primarily a COX-1 inhibitor at low dose [ie, 325 mg or less]) and a COX-2 inhibitor creates the ulcer risk of a traditional NSAID. A high percentage of individuals requiring cardioprotective doses of ASA have chronic pain and receive a traditional NSAID or a COX-2–selective NSAID (coxib). A survey that queried chronic coxib users found that 50% or more users were also taking ASA. Moreover, because coxibs were heralded as having an improved safety profile, related primarily to a lower rate of GI toxicity than traditional NSAIDs, the potential loss of this safety advantage when a COX-2 inhibitor is combined with ASA or an OTC NSAID remains underappreciated by clinicians. Heightened attention to the cardiovascular risks of NSAIDs has likely further increased the rate of addition of ASA to anti-inflammatory therapy.

**Mechanisms of Gastroduodenal Injury—Clopidogrel**

Platelet aggregation plays a critical role in healing through the release of various platelet-derived growth factors that promote angiogenesis. Angiogenesis, in turn, is critical for the repair of GI mucosal disruptions. Experimental animals with thrombocytopenia have been shown to have reduced ulcer angiogenesis and impaired ulcer healing. Additionally, adenosine diphosphate-receptor antagonists impair the healing of gastric ulcers by inhibiting platelet release of pro-angiogenic growth factors, such as vascular endothelial growth factor, which promotes endothelial proliferation and accelerates the healing of ulcers. GI bleeding is also a major toxic effect of chemotherapeutic agents that use monoclonal antibodies directed at circulating vascular endothelial growth factor. Although clopidogrel and other agents that impair angiogenesis may not be a primary cause of gastroduodenal ulcers, their anti-angiogenic effects may impair healing of gastric erosions or small ulcerations that develop because of other medications or *Helicobacter pylori* infection. This may then, in the presence of acid, lead to clinically significant ulceration and related complications.

**1. GI Complications of ASA and Non-ASA NSAIDs**

**Recommendation:** As the use of any NSAID, including COX-2–selective agents and OTC doses of traditional NSAIDs, in conjunction with cardiac-dose ASA, substantially increases the risk of ulcer complications, a gastroprotective therapy should be prescribed for at-risk patients.

Upper gastrointestinal events (UGIE), symptomatic or complicated ulcers, occur in 1 of every 20 NSAID users and in 1 of 7 older adults using NSAIDs, accounting for 30% of UGIE-related hospitalizations and deaths. Dyspepsia, defined as upper abdominal pain or discomfort, may occur in individuals taking NSAIDs, including ASA. Dyspepsia is not clearly predictive of the presence of an ulcer, as it is far more prevalent. Some patients may also experience an increase in symptoms of gastroesophageal reflux disease on NSAIDs as well. Endoscopic ulcers are used as a surrogate marker in clinical trials for risk of medications and in treatment trials; this document focuses on patients with dyspepsia and an ulcer (symptomatic ulcer) or those with serious (life threatening) ulcer complications such as bleeding or perforation. The annual incidence of NSAID-related UGIE is 2.0% to 4.5%, and the risk of bleeding, perforation, or obstruction is 0.2% to 1.9%. NSAIDs contribute to 10 to 20/1000 hospitalizations per year and are associated with a 4-fold increase in mortality. In the United States alone, NSAID use has been extrapolated to account for approximately 107 000 hospitalizations and 16 500 deaths per year among patients with arthritis. More recent information regarding these estimates related to NSAIDs suggests that these numbers may be too high, but increasing use of antplatelet medications may contribute to an increased burden of GI bleeding.26–28 According to these reports, GI hospitalization rates markedly declined (from 1.5% to 0.5%) between 1992 and 2000. Four potential explanations were given: use of lower doses of NSAIDs, less use of “more toxic” NSAIDs, increased use of “safer” NSAIDs, and increased use of proton pump inhibitors (PPIs).

Among elderly veterans, NSAID exposure has been shown to increase risk of UGIE-related mortality 3-fold, even after adjustment for advancing age, comorbidity, and proportion of time spent on a traditional or COX-2–selective NSAID. In fact, if deaths resulting from NSAID-associated upper GI complications were tabulated separately, it would represent the 15th most common cause of death in the United States. National data from the Department of Veterans Affairs reveal that 43.0% of the veterans prescribed NSAIDs are considered to be at high risk for UGIE and that patients 65 years or older constitute the largest high-risk subset (87.1%). Among elderly veterans, the risk of NSAID-related UGIE has been estimated to 2753 UGIE in 220 662 person-years of follow-up.
Those who combine an NSAID with ASA represent another high-risk group. When patients combine an NSAID with ASA, the annual risk of UGIE is 5.6%, with coxibs providing no additional gastroprotection (7.5% UGIE/year).

A number of observational studies have noted a 2- to 4-fold increased risk of UGIE associated with the concomitant prescription of NSAIDs with low-dose ASA. Data from Scandinavia indicated an annual incidence of hospital admission for UGIE of 1.4% related to use of NSAIDs plus low-dose ASA versus 0.6% for low-dose ASA. Estimates of the relative risk (RR) of UGIE for NSAID plus ASA range from 3.8 (95% confidence interval [CI]: 1.8 to 7.8) \(^{14}\) to 5.6 (95% CI: 4.4 to 7.0) when compared with ASA alone.\(^{30}\)

Endoscopic trials suggest that the GI toxicity of a coxib plus ASA is additive, resulting in an overall risk of endoscopic ulcer formation that parallels that seen with a nonselective NSAID.\(^{25,31}\) Additionally, evidence from observational studies and randomized controlled trials (RCTs) reveals that the risk of an NSAID plus ASA exceeds that of a coxib plus ASA, although both were markedly increased by ASA \(^{9,27,29}\). In this context, whether one chooses a nonselective NSAID or a selective COX-2 inhibitor has a minimal, and perhaps clinically insignificant, impact on the likelihood of serious adverse GI outcomes. Thus, the selection of anti-inflammatory drug therapy in such patients must involve consideration of overall GI risk reduction.

Recommendation: The use of low-dose ASA for cardioprophylaxis is associated with a 2- to 4-fold increase in UGIE risk. Enteric-coated or buffered preparations do not reduce the risk of bleeding. For patients at risk of adverse events, gastroprotection should be prescribed. The risk of UGIE increases with ASA dose escalation; thus, for the chronic phase of therapy, doses greater than 81 mg should not be routinely prescribed.

The AHA recommends low-dose ASA use among patients with a 10-year cardiovascular risk that is greater than or equal to 10%,\(^ {33,34}\) and the US Preventive Services Task Force recommends ASA cardioprophylaxis for patients with a 5-year risk of greater than or equal to 3%.\(^ {35}\) It has been estimated that 50 million Americans use low-dose ASA (ie, 325 mg/day or less) regularly for cardioprophylaxis.\(^ {36}\) The use of low-dose ASA is associated with a 2- to 4-fold increased risk of UGIE,\(^ {37,38}\) which is not reduced by the use of buffered or enteric-coated preparations.\(^ {39,40}\) Fourteen randomized placebo-controlled trials have presented data on UGIE with cardiac-dose ASA (75 to 325 mg per day) in adults. When these data are pooled, the absolute increased risk per year of UGIE with ASA is 0.12% when compared with placebo (number needed to harm = 833), with conflicting evidence of risk reduction with lower doses (75 mg to 162.5 mg) versus higher doses (greater than 162.5 to 325 mg).\(^ {41}\)

The estimated average excess risk of UGIE related to cardioprophylactic doses of ASA is 5 cases per 1000 ASA users per year.\(^ {42}\) Among elderly patients, the odds ratios (ORs) of bleeding with daily doses of ASA of 75, 150, and 300 mg are 2.3, 3.2, and 3.9, respectively.\(^ {37}\) Dose reduction does not appear to reduce antithrombotic benefits; however, dose escalation does seem to increase bleeding complications.\(^ {43}\) Additionally, case series implicate OTC use of low-dose ASA in over one third of the patients admitted for GI hemorrhage,\(^ {44}\) suggesting that patients who self-medicate may be unaware of the significant increase in their risk of UGIE.

The complexities of confirming a significant difference across the range of the low doses of ASA used for cardio-protection are discussed below. Meta-analyses have been contradictory in demonstrating a significant difference in the risk of GI bleeding.\(^ {45,46}\) Observational studies are somewhat contradictory, supporting evidence of a trend for an association between higher ASA dose and risk of upper GI complications.\(^ {37,47}\) The ACC and AHA recommend lowering the dose from 325 to 81 mg among those with a high risk of UGIE.\(^ {2}\) However, some experts feel it may be prudent to use up to 325 mg a day of ASA for 1 month after a stent procedure, although it is not clear from the data whether this dose is really necessary.\(^ {2}\) While this low-dose ASA approach makes sense intuitively because of the lack of demonstrated additional cardiovascular benefits at the higher dose (with certain limited exceptions, such as acute coronary syndrome [ACS]), coupled with a likelihood of increased risk of GI harm at the higher dose, the key point is that the benefit, in terms of GI bleeding risk reduction with the lower dose, remains insufficient to protect high-risk patients and mandates the addition of other GI bleeding risk-reduction approaches. However, it is unknown what the optimal dose of ASA really is. The Antithrombotic Trialists’ Collaboration meta-analysis provides indirect evidence that higher doses of ASA are not more effective, at least at a population level.\(^ {48}\) There are observational data from the CURE (Clopidogrel in unstable angina to prevent recurrent events) trial that suggest no benefit from higher doses of ASA but a greater risk of bleeding.\(^ {49}\) The CURRENT/OASIS-7 (Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Event Strat) trial is randomizing ACS patients to higher (300 to 325 mg) or lower (75 to 100 mg) ASA doses in the range used for cardiovascular disease and may help to clarify this issue once the results are known.

The use of enteric-coated or buffered formulations does not appear to reduce the risk of GI bleeding complications,\(^ {39,40,50}\) a finding that suggests that the upper GI side effects of ASA are a result of a systemic effect, in addition to its potent topical action to induce chemical injury. Anecdotal reports of reduced dyspepsia with these products likely contribute to their uptake in practice.\(^ {51}\)

While the risk factors for NSAID-related UGIEs have been well characterized, there are much less data on the risk of antiplatelet therapy. The synergism between ASA and NSAIDs was reviewed in detail in the previous section. A history of peptic ulcer, particularly with asso-
citated bleeding, appears to be the most important risk factor. Age is an important risk factor as well, with the relative increase beginning at age 60 years and rising in a nonlinear fashion with age. Gender is a less important concern, although the risk of men is slightly higher than that of women. The risk associated with combination antiplatelet and anticoagulant therapies is substantial as well, and each is discussed below given their importance in cardiology clinical practice.

3. GI Effects of Combined ASA and Anticoagulant Therapy

Recommendation: The combination of ASA and anticoagulant therapy (including unfractionated heparin, low-molecular-weight heparin, and warfarin) is associated with a clinically meaningful and significantly increased risk of major extracranial bleeding events, a large proportion from the upper GI tract. This combination should be used with established vascular, arrhythmic, or valvular indication; patients should receive concomitant PPIs as well. When warfarin is added to ASA plus clopidogrel, an international normalized ratio (INR) of 2.0 to 2.5 is recommended.62

The use of antiplatelet drugs for the initial management of ACS is common and known to be effective. In some clinical settings, such as the initial and long-term management of ACS, the combination of anticoagulant and antiplatelet therapy is superior to antiplatelet therapy alone but is associated with a substantial increase in UGIE, as shown in observational studies and multiple RCTs.

A meta-analysis of 4 RCTs of unfractionated heparin plus ASA versus ASA alone for ACS demonstrated a 50% increase in major bleeds, representing an excess of 3 major bleeds per 1000 patients. Low-molecular-weight heparin given in conjunction with ASA also increases major bleeding, as demonstrated in the FRISC-1 (Fragmin during Instability in Coronary Artery Disease-1) study and CREATE (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation). A comprehensive meta-analysis of over 25307 patients demonstrated that the benefits of adding warfarin to ASA in the treatment of ACS must be weighed against a 2-fold increased risk in major extracranial bleeding (OR 2.4; 95% CI: 1.4 to 4.1), suggesting that as few as 67 additional patients would need to be treated with ASA plus warfarin to result in 1 additional major extracranial bleeding event.

Conditions such as venous thromboembolism or mechanical heart valves may necessitate long-term anticoagulation. With certain mechanical heart valves, an INR target of 2.0 to 2.5 may not be appropriate, and a higher INR may be required. Depending on the patient’s specific bleeding and thrombotic risks, consideration may be given to stopping the antiplatelet agent, as warfarin also has cardioprotective effects.

4. GI Effects of Clopidogrel

Recommendation: Substitution of clopidogrel for ASA is not a recommended strategy to reduce the risk of recurrent ulcer bleeding in high-risk patients and is inferior to the combination of ASA plus PPI.

Because of their alternative molecular targets and inhibition of platelet activation, thienopyridines (ie, clopidogrel, ticlopidine) taken on their own, or in combination with ASA, have been compared with ASA. The ACC/AHA practice guidelines recommend the use of clopidogrel for hospitalized patients with ACS who are unable to take ASA because of major GI intolerance (Class I, Level of Evidence: A recommendation). This recommendation was largely based on the safety data of the CAPRIE (Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events) study. This study compared clopidogrel 75 mg daily with a relatively high cardioprotective dose of ASA (325 mg daily) for the prevention of ischemic events, including myocardial infarction, stroke, and peripheral arterial disease. After a median follow-up of 1.91 years, the incidence rate of major GI bleeding was lower in the clopidogrel group (0.52%) when compared with the ASA group (0.72%; P < 0.05). The rate of hospitalization for GI bleeding was 0.7% with clopidogrel versus 1.1% with ASA (P = 0.012). Although the risk of GI bleeding with clopidogrel was lower than that with ASA, the difference was small. Clopidogrel with ASA for at least 1 month is also recommended for patients with a recent non-ST-segment elevation-ACS, with a preference of 12 months if the bleeding risk is not high. In patients who have received drug-eluting stents, at least 12 months of uninterrupted dual antiplatelet therapy is recommended.

Data from the CURE, MATCH (Management of Atherothrombosis with Clopidogrel in High-Risk Patients), CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) studies provide confirmatory evidence that combined ASA and clopidogrel therapy is associated with significantly increased risk of UGIE complications when compared with either agent alone. In patients at high risk of bleeding who require a stent, a bare-metal stent, with its shorter requisite duration of dual antiplatelet therapy, may be preferable.

Concomitant use of clopidogrel and an NSAID (including low-dose ASA) has been associated with impaired healing of asymptomatic ulcers and disruption of platelet aggregation, with a consequent increase in serious UGIE (OR 7.4; 95% CI: 3.5 to 15). Few human studies document clopidogrel’s potential for independent injury to the GI mucosa. A single endoscopic study with limited follow-up failed to demonstrate mucosal injury in humans. In a hospital-based, case-control study of 2777 consecutive patients with major upper GI bleeding and 5532 controls, it was found that non-ASA antiplatelet drugs (clopidogrel, ticlopidine) had a similar risk of upper GI bleeding (adjusted RR 2.8; 95% CI: 1.9 to 4.2) to ASA, at a dose of 100 mg/day (adjusted RR 2.7; 95% CI: 2.0 to 3.6), or anticoagulants (adjusted RR 2.8; 95% CI: 2.1 to 3.7).

A prospective, double-blind RCT comparing ASA plus esomeprazole against clopidogrel among H pylori–negative patients with recent UGIE secondary to low-dose ASA demonstrated a significantly higher proportion of recurrent UGIE in the clopidogrel arm versus the ASA plus esomeprazole (20 mg twice daily) arm during the 12 months of study.
(8.6% versus 0.7%; 95% CI on the difference: 3.4% to 12.4%). A subsequent randomized trial with very similar design has shown virtually identical results (13.6% UGIE in the clopidogrel group versus 0% in the ASA plus esomeprazole group [20 mg daily]; 95% CI on the difference: 6.3% to 20.9%). These data suggest that use of clopidogrel alone to reduce GI bleeding as an alternative to ASA is not a safe strategy and support ASA cotherapy with once-daily PPI. It remains unclear whether clopidogrel exerts an independent injurious effect on the GI mucosa, or whether it merely induces bleeding in already damaged mucosa via its antiplatelet effects. Observational studies have suggested that PPI cotherapy is beneficial to reduce the risk of clopidogrel monotherapy as well.

5. GI Effects of Combined Clopidogrel and Anticoagulant Therapy

Recommendation: The combination of clopidogrel and warfarin therapy is associated with an increased incidence of major bleeding when compared with monotherapy alone. Use of combination antiplatelet and anticoagulant therapy should be considered only in cases in which the benefits are likely to outweigh the risks. When warfarin is added to ASA plus clopidogrel, an INR of 2.0 to 2.5 is recommended.

A paucity of evidence informs the clinical risk of combination therapy with clopidogrel or ticlopidine. Anticoagulant agents are not by themselves ulcerogenic; however, they are associated with an increased risk of UGIE because of an exacerbation of pre-existing lesions in the GI tract associated with NSAIDs, ASA, or H pylori infection. Clinically, this combination of ASA plus clopidogrel or ticlopidine together with anticoagulation, while not routinely recommended, is sometimes utilized among patients with atrial fibrillation, peripheral arterial disease, and coronary artery disease with percutaneous coronary intervention. With certain mechanical heart valves, an INR target of 2.0 to 2.5 may be too low, and a patient’s individual thrombotic and bleeding risks need to be assessed.

The WAVE (Warfarin and Vascular Evaluation) study randomized 2161 patients with peripheral arterial disease to receive warfarin plus antiplatelet therapy (ASA or thienopyridine) or warfarin monotherapy. No substantial difference was noted in the composite cardiovascular outcome of myocardial infarction, stroke, or death; however, more bleeding events requiring significant transfusion or surgical intervention were noted among patients receiving combination therapy (RR 3.4; 95% CI: 1.8 to 6.4), despite the fact that few participants had an INR in excess of 3.0. Unfortunately, the number of patients prescribed ticlopidine or clopidogrel in combination with an anticoagulant in the WAVE trial was very small (6%); thus, the magnitude of risk of combined anticoagulant-thienopyridine therapy remains unclear. However, despite a priori exclusion of patients on NSAIDs and with prior history of UGIE, nearly 30% of patients terminated anticoagulation therapy because of bleeding episodes; no comment was made on the number of major bleeding events that originated from the GI tract. In a recent article describing bleeding risk in patients receiving triple therapy with ASA, clopidogrel, and anticoagulation, the incidence of both major and minor bleeding was substantially increased. Such combination therapy should be maintained only in patients in whom the benefit in cardiovascular protection outweighs these significant risks and a combination therapy with chronic PPI use seems prudent.

6. Treatment and Prevention of ASA- and NSAID-Related Gastrointestinal Injury

Recommendation: PPIs are the preferred agents for the therapy and prophylaxis of NSAID- and ASA-associated GI injury.

The selection of patients for therapy to reduce the risk of antplatelet therapy should consider the risk factors discussed in the preceding section, as well as concurrent medical illness. A suggested approach is outlined in Figure 1. Given the relative safety of cotherapy to reduce risk, consideration of risk factors mainly relates to the provision of cost-effective care.

Prostaglandin depletion is the central mechanism for NSAID–ulcer development, and replacement therapy with the synthetic prostaglandin, misoprostol, reduces NSAID toxicity. Little data specifically address the impact of misoprostol on ASA-related injury, although one would expect, given the reduced ulcerogenic effects of low-dose ASA compared with those of full-dose NSAIDs, that it would be effective for that purpose as well. In an endoscopic study, misoprostol 100 mcg/day significantly reduced the development of erosions in healthy volunteers taking ASA 300 mg/day. In addition, misoprostol has been shown to be superior to placebo for preventing recurrence of gastric ulcers among patients with a history of gastric ulcer who were receiving low-dose ASA and another NSAID. However, misoprostol is associated with side effects, particularly diarrhea, that often lead to treatment discontinuation. For example, in a study of more than 8000 rheumatoid arthritis patients, 20% of patients receiving misoprostol withdrew within the first month of treatment because of diarrhea. Although it is the only US Food and Drug Administration–approved regimen for the prevention of NSAID ulcers and complications, it is rarely used because of the prevalence of the side effects of diarrhea and abdominal cramping.

Sucralfate, a basic aluminum salt of sucrose octasulfate, forms an ulcer-adherent complex at duodenal ulcer sites, protecting the ulcer and promoting healing; sucralfate may also inhibit pepsin activity in gastric fluid. Sucralfate has been shown to be effective in the treatment of NSAID-associated duodenal ulcers, particularly when the NSAID is stopped, but is not effective in the treatment or prevention of NSAID-related gastric ulcers. Its use is not recommended because of the availability of far superior alternatives.

The level of acid suppression provided by traditional doses of H2-receptor antagonists (H2RAs) does not prevent most NSAID-related gastric ulcers. There are little data on their use in conjunction with ASA. The H2RA ranitidine, at a dose of 150 mg/day, significantly increased intragastric pH and reduced the amount of gastric bleeding in subjects taking ASA 300 mg/day. Similar results were seen in 2 further trials in volunteers. Despite a single endoscopic study demonstrating that H2RAs at double the usual dose may be effective...
compared with placebo, studies comparing high doses of H2 blockers to misoprostol or PPIs for the prevention of NSAID ulcers are not available. Given compliance concerns with twice-daily dosing, PPI therapy is the rational alternative to H2RAs in this clinical setting. PPIs have been proven superior to both ranitidine and misoprostol in preventing NSAID ulcer recurrence and overall symptom control, largely related to their ability to reduce ulcers and improve NSAID-associated dyspepsia, thereby affecting overall quality of life. No randomized controlled data are available from studies evaluating the impact of H2 blockers on low-dose ASA-related injury.

PPIs inhibit the parietal cell proton pump, thus exerting a suppressive effect on gastric acid. In endoscopic studies involving healthy volunteers, both lansoprazole and omeprazole significantly reduced the risk of gastroduodenal lesions in patients taking ASA 300 mg/day.51 These results were confirmed by epidemiological studies in which concomitant antisecretory therapy, especially PPI therapy, was associated with a significant RR reduction of upper GI bleeding among patients receiving low-dose ASA.76,84 These data in the literature do not demonstrate evidence that supports the need for greater than the standard once daily dosing for PPI therapy as indicated in labeling for ulcer disease indications, despite the greater levels of acid suppression afforded by more frequent or higher daily dosing. Maximal acid inhibitory effects of most PPIs are achieved if food is consumed within 30 minutes of dosing; this is most relevant for gastroesophageal reflux disease symptom control, but it is not known if this concern is relevant for ulcer prevention therapy.

Lansoprazole 30 mg/day was compared with placebo for recurrence of ulcer complications in patients taking ASA 100 mg/day for 12 months after eradication of H pylori and healing of ulcers. Patients in the lansoprazole group were significantly less likely to have a recurrence of ulcer complications, suggesting that PPI therapy plus H pylori eradication is superior to H pylori eradication alone.85 Although 4 of 9 patients in the placebo group who rebled had either failed eradication or had H pylori reinfection, this study indicates that antibiotic treatment alone provides insufficient protection for low-dose ASA users at high risk. Chan et al86 reported that among patients with H pylori infection and a history of upper GI bleeding, omeprazole therapy was equivalent to eradication of H pylori in preventing recurrence of bleeding. However, the follow-up time in this study was relatively short (6 months). In an observational study, Lanas et al87 reported a low incidence of upper GI complications among high-risk patients receiving low-dose ASA plus omeprazole.

As discussed elsewhere, the predominant antiplatelet effect of ASA promotes bleeding from established lesions (including H pylori–induced ulcers) and creates new ulcers. Based upon data on full-dose NSAID therapy, PPI therapy is believed to tip the balance so that small lesions do not progress to larger lesions that can become symptomatic.88 This is important, as observational studies with the occurrence of GI hemorrhage as their end point may document changes in the rate of ulcer bleeding but fail to

Figure 1. Steps for minimizing gastrointestinal bleeding. PPI therapy is believed to reduce the risk in all patients; the more risk factors present, the more cost-effective the additional therapy likely becomes. See text for additional considerations. GI indicates gastrointestinal; GERD, gastroesophageal reflux disease; and PPI, proton pump inhibitor.
assess the prevalence of ASA-related ulcers. This is very relevant to the interpretation of case-controlled studies from areas of high \textit{H pylori} prevalence, which, indeed, provide much of the data on this issue and which also suggest a possible role for H2RA therapy. The administration of an H2RA, by reducing the burden of \textit{H pylori}–related ulcers, lessens the likelihood of GI bleeding events related to the antiplatelet effect of ASA therapy.\cite{76,84}

Combining a PPI with clopidogrel appears to result in less GI bleeding.\cite{76,89} To date, despite some in vitro data to suggest an interaction due to metabolism by the cytochrome P450 pathway, there has been relatively little evidence of any clinically significant interaction between clopidogrel and PPIs.\cite{89} The ongoing COGENT-1 (Clopidogrel and the Optimization of Gastrointestinal Events; NCT00557921) study is randomizing patients with coronary artery disease to ASA plus clopidogrel in combination with omeprazole 20 mg or placebo and should provide further evidence to help address these issues.

### 7. Role of \textit{H pylori}

**Recommendation: Testing for and eradicating \textit{H pylori} in patients with a history of ulcer disease is recommended before starting chronic antiplatelet therapy.**

Unlike results of studies among non-ASA NSAID users, case-control studies have consistently shown that \textit{H pylori} is an important risk factor for ulcer and ulcer bleeding in users of low-dose ASA.\cite{38,91,92} In a case-control study of 695 consecutive users of low-dose ASA with upper GI bleeding, \textit{H pylori} infection was identified as an independent risk factor of upper GI bleeding (OR 4.7; 95% CI: 2.0 to 10.9). Other risk factors identified were a previous ulcer history (OR 15.2; 95% CI: 3.8 to 60.1), alcohol use (OR 4.2; 95% CI: 1.7 to 10.4), and use of calcium-channel blockers (OR 2.54; 95% CI: 1.25 to 5.14).\cite{91}

Whether eradication of \textit{H pylori} infection in patients with a history of ulcer prior to starting ASA will reduce subsequent ulcer risk has been controversial. In a 6-month randomized trial of \textit{H pylori} eradication versus maintenance therapy with omeprazole in ASA users with \textit{H pylori} infection and a recent history of ulcer bleeding (n=250), rates of recurrent ulcer bleeding were comparable between the 2 treatment groups (1.9% in the eradication therapy group and 0.9% in the omeprazole group; 95% CI for the difference: −1.9% to 3.9%).\cite{88} In another randomized trial, all ASA users with \textit{H pylori} infection and a history of ulcer bleeding received a course of eradication therapy. They were then randomly assigned to receive lansoprazole (n=62) or placebo (n=61) for up to 12 months. It was found that 1.6% (95% CI: 0% to 9%) of patients in the lansoprazole group compared with 14.8% (95% CI: 7% to 26%) in the placebo group had recurrent ulcer bleeding.\cite{85} In the latter study, however, two-thirds of the patients with recurrent ulcer bleeding in the placebo group either had failed of \textit{H pylori} eradication or used concomitant NSAIDs. Thus, whether eradication of \textit{H pylori} alone would adequately reduce the risk of ulcer bleeding in ASA users with high GI risk is uncertain. Nevertheless, prophylaxis with a PPI effectively prevents recurrent upper GI bleeding with low-dose ASA, despite failure of \textit{H pylori} eradication and concomitant use of non-ASA NSAIDs.

A more recent study, and the largest to date, has gone some way toward clarifying this issue. In this prospective cohort study, the incidence rates of ulcer bleeding were compared among 3 different cohorts of low-dose ASA users, namely, patients without prior ulcer history who just started using ASA (n=548), ASA users with prior ulcer bleeding and \textit{H pylori} infection who had successful eradication of \textit{H pylori} (n=250), and \textit{H pylori}–negative ASA users who had prior ulcer bleeding (n=118). All patients received low-dose ASA (less than 160 mg daily) without a gastroprotective agent. After a median follow-up of 48 months, the annualized incidence rate of ulcer bleeding in the 3 groups was 0.5%, 1.1%, and 4.6%, respectively.\cite{93} Thus, current evidence suggests that confirmed eradication of \textit{H pylori} in ASA users with prior ulcer bleeding significantly and substantially reduces the risk of recurrent bleeding. Whether this strategy would be beneficial in emergent situations such as ACS is unknown.

#### A. Diagnosis of \textit{H pylori}

A recently published ACG guideline provides a comprehensive source of information on \textit{H pylori}.\cite{94} Noninvasive \textit{H pylori} testing is currently recommended for patients who do not need endoscopy. Two general categories of noninvasive tests are now available: tests that identify active infection and tests that detect antibodies (exposure). This distinction is important because antibodies (ie, positive immune response) indicate only the presence of \textit{H pylori} at some time. Antibody tests do not differentiate between previously eradicated and currently active \textit{H pylori}. Compared with tests for active infection, tests for antibodies are simpler to administer, provide a faster result, and are less expensive. However, the probability that a positive antibody test reflects active infection decreases as the proportion of patients with previously eradicated \textit{H pylori} increases. Successfully treated patients include both patients given antibiotics specifically for \textit{H pylori} and patients with undiagnosed \textit{H pylori} who had their \textit{H pylori} eradicated by antibiotics given for another infection; less common is spontaneous eradication of \textit{H pylori} infection.

\textit{H pylori} serologic tests that detect antibodies to \textit{H pylori} have a sensitivity and specificity of approximately 90%. In populations with low disease prevalence, the positive predictive value of the test falls dramatically, leading to unnecessary treatment. Office-based serologic tests are less accurate than laboratory-based enzyme-linked immunosorbent assay tests but have the advantage of providing a result within 30 minutes. Serology tests should be used only for initial diagnosis, because antibody levels often remain elevated after \textit{H pylori} is eliminated. Serology tests should not be used to confirm a cure after a patient has been treated for \textit{H pylori}.

#### B. Tests for Active \textit{H pylori}

Tests for active \textit{H pylori} include fecal \textit{H pylori} antigen testing and urea breath testing (UBT). For the UBT, the patient drinks an oral preparation containing \textsuperscript{13}C- or \textsuperscript{14}C-labeled urea. \textit{H pylori} bacteria in the stomach metabolize this urea; the bloodstream absorbs the carbon and it travels to the lungs, which exahle it as carbon dioxide. The carbon dioxide isotope
is measured to determine the presence or absence of \textit{H pylori}. This test has a sensitivity and specificity of more than 90\% for active infection. A number of drugs can adversely affect the accuracy of UBT. Prior to any form of active testing, antibiotics and bismuth should be withheld for at least 4 weeks, PPIs should be withheld for at least 7 days, and patients should fast for at least 6 hours.

The stool antigen test has been reported to have a sensitivity and specificity of more than 90\% in untreated patients with suspected \textit{H pylori} infection. It requires collection of a stool sample the size of an acorn by either the clinician or the patient. This test must be performed in a laboratory by trained personnel. Based upon available data, it is reasonable to conclude that the fecal antigen test can be used interchangeably with the UBT to identify \textit{H pylori} before antibiotic therapy.

\section*{C. Treatment of \textit{H pylori}}

The choice of therapy should consider effectiveness and cost of various regimens versus side effects. PPIs have in vitro activity against \textit{H pylori}. A PPI plus clarithromycin (500 mg) plus either amoxicillin (1 g) or metronidazole (500 mg) given twice daily has demonstrated eradication rates near 90\% when used for 10 to 14 days. Amoxicillin is preferred for patients who have been treated with metronidazole previously. Metronidazole is preferred for patients allergic to penicillin. “Bismuth-based triple therapy” is a less costly alternative: (bismuth subsalicylate) 2 tablets daily, metronidazole 250 mg four times daily, and tetracycline 500 mg four times daily for 2 weeks is the best studied, highly effective anti–\textit{H pylori} therapy (greater than or equal to 85\% eradication). The duration and multidrug nature of this regimen have been associated with decreased compliance, leading to potential failure to eradicate. The complexity of testing and treatment of \textit{H pylori}, despite its apparent value as a sole therapy to reduce risk, supports the superiority of PPI therapy alone in its simplicity and efficacy, even for \textit{H pylori}–infected patients, as demonstrated by the study by Lai et al.\textsuperscript{85}

\section*{8. Discontinuation of Antiplatelet Therapy Because of Bleeding}

\textbf{Recommendation:} Decision for discontinuation of ASA in the setting of acute ulcer bleeding must be made on an individual basis, based upon cardiac risk and GI risk assessments to discern potential thrombotic and hemorrhagic complications.

Patients receiving low-dose ASA who develop upper GI bleeding are often advised to discontinue ASA until ulcers have healed. A particular dilemma arises in patients requiring continuous antiplatelet therapy (eg, with ACS, acute cerebrovascular insufficiency, or recent percutaneous revascularization) who develop actively bleeding ulcers. Can ASA be reintroduced immediately after endoscopic hemostasis has been achieved, given that prolonged discontinuation of ASA increases thrombotic risk in patients with unstable cardiovascular diseases?

Hemodynamic instability and hemostatic changes induced by acute bleeding may further increase the risk of thrombosis in the absence of antiplatelet therapy. On the other hand, continuation of ASA in the setting of acute ulcer bleeding may provoke recurrent bleeding. There is no evidence that non-ASA antiplatelet drugs such as clopidogrel will reduce this bleeding risk in the presence of active ulcers.\textsuperscript{73} A meta-analysis of randomized trials showed that the intravenous administration of a PPI after endoscopic therapy for bleeding ulcers reduced the risk of recurrent bleeding (OR 0.39; 95\% CI: 0.18 to 0.87) and the need for surgery (OR 0.61; 95\% CI: 0.40 to 0.93).\textsuperscript{96} However, no previous trials permitted continuation of antiplatelet therapy during the study period. An in vitro study suggested that hemostasis depends on pH and the stability of the platelet plug.\textsuperscript{96} Antiplatelet drugs may negate the hemostatic effect of a PPI by impairing platelet-plug formation.

To date, only 1 small-scale, double-blind, randomized trial evaluated the effect of early reintroduction of ASA in patients with cardiovascular diseases who presented with acute bleeding ulcers.\textsuperscript{97} By the time that an interim analysis was performed, 113 patients receiving ASA for cerebrovascular or cardiovascular diseases who developed bleeding gastroduodenal ulcers confirmed by endoscopy had been enrolled. After endoscopic control of active bleeding, they were randomly assigned to receive ASA 80 mg once daily or placebo. All patients received a continuous infusion of a PPI for 72 hours and then a standard dose of an oral PPI for up to 8 weeks. The end points included recurrent ulcer bleeding within 30 days and all-cause mortality. The 2 groups were comparable in terms of age (mean age 74 years versus 73 years), gender (men: 62\% versus 69\%), prior ulcer history (6.9\% versus 3.7\%), concomitant use of NSAIDs (12\% versus 11\%), location (gastroduodenal ulcers: 28 versus 32), and diameter of ulcers (1.13 cm versus 1.20 cm). Recurrent ulcer bleeding within 30 days occurred in 18.9\% of patients receiving ASA and 10.9\% receiving placebo ($P=0.25$). In the ASA group, 1 patient (1.7\%) died of a recurrent cardiovascular event. In the placebo group, 8 patients (14.5\%) died (5 recurrent cardiovascular events, 2 recurrent bleeding, and 1 pneumonia; $P=0.01$ versus ASA group). These results suggested that the discontinuation of ASA was associated with a significant increase in all-cause mortality, with most of the deaths being due to recurrent cardiovascular events. There was a numerical trend toward a higher rate of recurrent ulcer bleeding in the ASA group (18.9\%), which suggested that adjuvant PPI after endoscopic therapy could not effectively prevent early rebleeding induced by ASA.

\section*{9. Endoscopy in Patients on Mono- or Dual Antiplatelet Therapy}

\textbf{Recommendation:} Endoscopic therapy may be performed in high-risk cardiovascular patients on dual antiplatelet therapy, and collaboration between the cardiologist and endoscopist should balance the risks of bleeding with thrombosis with regard to the timing of cessation of antiplatelet therapy.

The American Society of Gastrointestinal Endoscopy practice guideline\textsuperscript{98} on the use of antiplatelet and anticoagulant medications in the setting of GI endoscopy considers the risks and benefits of antiplatelet therapy with the need for, and risks of, GI endoscopy with intervention. With regard to the
performance of GI endoscopy in the setting of multiple antiplatelet agents, it is quite clear that cardiovascular concerns should remain paramount in the GI endoscopist’s practice; thus, cardiovascular risk weighs heavily in clinical decision making. While many endoscopists would prefer to withhold dual antiplatelet agents in the setting of an elective colonoscopy and polypectomy, the actual evidence that this practice reduces the risk of post-polypectomy bleeding is marginal, at best.99 Therefore, we encourage endoscopists to consider cardiovascular risks and to defer elective procedures in patients in whom a high risk is present (eg, those with recent placement of cardiovascular stents), for example, for a year after drug-eluting stent placement. It is important to emphasize that the guideline does not mandate discontinuation of ASA or NSAIDs for most endoscopic procedures because of a lack of clear evidence that bleeding rates following an endoscopic procedure, such as a polypectomy, are adversely influenced.

The most likely setting where the issue of possibly discontinuing antiplatelet agents in a high-risk patient will arise will be that of endoscopic therapy for GI bleeding. This should be a rare occurrence, and again, individualized risk stratification should be paramount. Based on the expert consensus of the writing committee, for those with chronic blood loss and high cardiovascular risk, such as a recently placed stent, dual antiplatelet therapy should be continued as mandated by cardiovascular risk, given the lack of a clearly defined contraindication to endoscopic intervention.

In the acute setting following successful endoscopic and medical treatment of major GI hemorrhage, it seems prudent, following discussion among the specialties, to briefly discontinue antiplatelet therapy until lack of rebleeding is observed in the intensive care unit setting. The optimal duration for cessation of antiplatelet therapy leading to a balance of GI and cardiovascular outcomes has not been established by clinical trials. The current efficacy of endoscopic therapy for ulcer bleeding combined with intravenous continuous-infusion PPI therapy suggests that reintroduction of antiplatelet therapy in such high-cardiovascular-risk patients is reasonable in those who remain free of rebleeding after 3 to 7 days.97 In the far less common setting of endoscopic therapy for lower GI bleeding, even less available data guide decision making. Since there is no adjunctive medical therapy such as for ulcer bleeding with PPI, endoscopists may favor the use of nonthermal treatment approaches such as clipping and favor a delay of antiplatelet therapy for 7 to 10 days, based upon lesion size and individualized assessment of adequacy of endoscopic therapy.

Summary

In appropriate patients, oral antiplatelet therapy decreases ischemic risks, but this therapy may increase bleeding complications. Of the major bleeding that occurs, the largest proportion is due to GI hemorrhage. Concomitant use of NSAIDs further raises the risk of GI bleeding. Gastroprotection strategies consist of use of PPIs in patients at high risk of GI bleeding and eradication of _H pylori_ in patients with a history of ulcers. Communication between cardiologists, gastroenterologists, and primary care physicians is critical to weigh the ischemic and bleeding risks in an individual patient who needs antiplatelet therapy but who is at risk for or develops significant GI bleeding.

Staff

American College of Cardiology Foundation

John C. Lewin, MD, Chief Executive Officer

Charlene L. May, Associate Director, Clinical Policy

Dawn R. Phoubandith, MSW, Associate Director, Clinical Policy and Documents

Erin A. Barrett, Senior Specialist, Science and Clinical Policy

References


Downloaded from circ.ahajournals.org by on December 5, 2008


99. Key Words: AHA Scientific Statements • gastrointestinal risk • antiplatelet therapy • NSAID • gastroduodenal ulcer • gastrointestinal bleeding • aspirin • stents • thrombosis.
# Appendix 1. Author Relationships with Industry and Other Entities—ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Consulting Fees/Honoraria</th>
<th>Speakers' Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional or Other Financial Benefit</th>
<th>Expert Witness or Consultant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Deepak L. Bhatt</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>Bristol-Myers Squibb, Sanofi-Aventis—CHARISMA, PI*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer Healthcare</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cogentus Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis U.S. Inc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Takeda Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>North America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. James Scheiman</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca*</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bayer Healthcare</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Horizon Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TAP Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Neena S. Abraham</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TAP Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Elliott M. Antman</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Bayer Healthcare</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cogentus Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GlaxoSmithKline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roche Diagnostics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roche Diagnostics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>GmbH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Aventis—PI*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sanofi-Synthelabo</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Recherche</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Francis K. L. Chan</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>AstraZeneca—Co-Investigator</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Takeda Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>North America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr. Curt D. Furberg</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. David A. Johnson</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>AstraZeneca</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novartis Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Corporation*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TAP Pharmaceuticals*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
This table represents the relationships of committee members with industry and other entities that were reported by the authors as relevant to this topic during the document development process. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.

*Significant (greater than $10,000) relationship.

ACCF/ACG/AHA indicates American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association; NSAID, nonsteroidal anti-inflammatory drugs; and PI, principal investigator.

<table>
<thead>
<tr>
<th>Committee Member</th>
<th>Consulting Fees/Honoraria</th>
<th>Speakers' Bureau</th>
<th>Ownership/Partnership/Principal Research</th>
<th>Institutional or Other Financial Benefit</th>
<th>Expert Witness or Consultant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Kenneth W. Mahaffey</td>
<td>● Bayer Healthcare</td>
<td>● Sanofi-Aventis*</td>
<td>None</td>
<td>● AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td>● Novartis Pharmaceuticals Corporation*</td>
<td></td>
<td></td>
<td>● Bayer Healthcare*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Sanofi-Aventis*</td>
<td></td>
<td></td>
<td>● Bristol-Myers Squibb*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>● Sanofi-Synthelabo</td>
<td></td>
<td></td>
<td>● Novartis Pharmaceuticals Corporation*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>● Sanofi-Aventis*</td>
<td></td>
</tr>
<tr>
<td>Dr. Eamonn M. Quigley</td>
<td>None</td>
<td>● Nycomed*</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>● Reckitt Benckiser</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bhatt et al. ACCF/ACG/AHA Expert Consensus Document: Antiplatelets, NSAIDs, and GI Risk

1907

By on December 5, 2008
<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Consulting Fees/Honoraria</th>
<th>Speakers' Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional or Other Financial Benefit</th>
<th>Expert Witness or Consultant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Eric R. Bates</td>
<td>Official Reviewer—ACCF Task Force on Expert Consensus Documents</td>
<td>Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Craig B. Clark</td>
<td>Official Reviewer—ACCF Board of Governors</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Robert A. Harrington</td>
<td>Official Reviewer—ACCF Board of Trustees</td>
<td>Bayer*</td>
<td>None</td>
<td>None</td>
<td>Sanofi-Aventis</td>
<td>AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bristol-Myers</td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Squib</td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td>Dr. John Inadomi</td>
<td>Official Reviewer—ACG</td>
<td>AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TAP Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td>AstraZeneca*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Horizon Therapeutics</td>
<td></td>
<td></td>
<td></td>
<td>Santarus</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TAP Pharmaceuticals</td>
<td></td>
<td></td>
<td></td>
<td>TAP Pharmaceuticals</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Philip Katz</td>
<td>Official Reviewer—ACG</td>
<td>AstraZeneca*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bristol-Myers</td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb/Sanofi-Aventis*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Squib</td>
<td></td>
<td></td>
<td></td>
<td>Bristol-Myers Squibb/Sanofi-Aventis*</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sanofi-Aventis</td>
<td></td>
<td></td>
<td></td>
<td>Sanofi-Aventis</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Laurence Sperling</td>
<td>Official Reviewer—AHA</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Daniel I. Simon</td>
<td>Official Reviewer—AHA</td>
<td>Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Jeffrey S. Berger</td>
<td>Content Reviewer—ACCF Prevention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Roger S. Blumenthal</td>
<td>Content Reviewer—ACCF Prevention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Jeffrey J. Cavendish</td>
<td>Content Reviewer—ACCF Prevention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Jose G. Diez</td>
<td>Content Reviewer—ACCF Cardiac Catheterization and Intervention Committee</td>
<td>Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
<td>Sanofi-Aventis</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Steven P. Dunn</td>
<td>Content Reviewer—ACCF Prevention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Pamela B. Morris</td>
<td>Content Reviewer—ACCF Prevention Committee</td>
<td>AstraZeneca</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pfizer</td>
<td></td>
<td></td>
<td></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Takeda Pharmaceuticals North America</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None</td>
</tr>
<tr>
<td>Dr. Srihari S. Naidu</td>
<td>Content Reviewer—ACCF Cardiac Catheterization and Intervention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

(Continued)
### Appendix 2. Continued

<table>
<thead>
<tr>
<th>Peer Reviewer</th>
<th>Representation</th>
<th>Consulting Fees/Honoraria</th>
<th>Speakers' Bureau</th>
<th>Ownership/Partnership/Principal</th>
<th>Research</th>
<th>Institutional or Other Financial Benefit</th>
<th>Expert Witness or Consultant</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Robert S. Rosenson</td>
<td>Content Reviewer—ACCF Task Force on Clinical Expert Consensus Documents</td>
<td>None</td>
<td><em>AstraZeneca</em></td>
<td>None</td>
<td><em>AstraZeneca</em></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Dr. Nanette K. Wenger</td>
<td>Content Reviewer—ACC/AHA Guidelines on the Management of Patients With Unstable Angina/NSTEMI</td>
<td><em>AstraZeneca</em>, <em>Pfizer</em>, <em>Schering-Plough</em></td>
<td>None</td>
<td>None</td>
<td><em>Pfizer</em>, <em>Sanofi-Aventis</em></td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Ms. Marie J. Williams</td>
<td>Content Reviewer—ACCF Cardiac Catheterization and Intervention Committee</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

This table represents the relationships of peer reviewers with industry and other entities that were reported as relevant to this topic during the document development process. It does not necessarily reflect relationships at the time of publication. Participation in the peer review process does not imply endorsement of this document. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review.

*Significant (greater than $10,000) relationship.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACG, American College of Gastroenterology; AHA, American Heart Association; NHLBI, National Heart, Lung, and Blood Institute; NSAID, nonsteroidal anti-inflammatory drugs; and NSTEMI, non-ST-segment elevation myocardial infarction.